CompanyGraph
Hua Medicine Ltd.
2552 · HKEX · China
Price data from its HUMDF listing on OTC, quoted in USD
huamedicine.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 2.41: grey zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.34BHKD425.24M · vs all stocks (USD)
Revenue (TTM)
766.34MHKD97.68M · vs all stocks (USD)
Profit Margin
-16.47%Beta
0.8010xvs all stocks
52-Week Change
-45.76%vs all stocks
Market Capitalization
3.34BHKD425.24M · vs all stocks (USD)
Enterprise Value
1.85BHKD236.10M · vs all stocks (USD)
Forward P/E
-4.90xPrice to Sales (TTM)
3.51xPrice to Book (MRQ)
1.98xEnterprise to Revenue
2.42xEnterprise to EBITDA
-16.28xProfit Margin
-16.47%Operating Margin
-7.04%Return on Assets (TTM)
-4.53%Return on Equity (TTM)
-10.51%Revenue (TTM)
766.34MHKD97.68M · vs all stocks (USD)
Revenue per Share (TTM)
0.6580HKDUpdated Sep 20, 2026Quarterly Revenue Growth
74.30%Gross Profit (TTM)
464.72MHKD59.24M · vs all stocks (USD)
EBITDA (TTM)
-113.79MHKD-14.50M · vs all stocks (USD)
Net Income (TTM)
-126.22MHKD-16.09M · vs all stocks (USD)
Operating Cash Flow (TTM)
-35.75MHKD-4.56M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-9.66MHKD-1.23M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Sep 20, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
492.93MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
212.58MCNYFY2025 · Dec 31, 2025Gross Profit
280.36MCNYFY2025 · Dec 31, 2025Operating Income
-135.95MCNY-20.29M · vs all stocks (USD)
Pre-tax Income
1.11BCNYFY2025 · Dec 31, 2025Income Tax Expense
0.00CNYFY2025 · Dec 31, 2025Net Income
1.11BCNYFY2025 · Dec 31, 2025EBIT
1.11BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-96.53MCNYFY2025 · Dec 31, 2025Research & Development
145.32MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
279.92MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
11.49MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
8.15MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.12CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.10CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
987.82MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
987.82MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.11BCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-138.62MCNYFY2025 · Dec 31, 2025Free Cash Flow
-146.17MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.09BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.11BCNYFY2025 · Dec 31, 2025Stock-based Compensation
12.19MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-1.25BCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-21.85MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
13.91MCNYFY2025 · Dec 31, 2025Capital Expenditures
-7.55MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00CNYFY2025 · Dec 31, 2025Other Investing Activity
-2.25MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-9.80MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
112.43MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-98.28MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
36.62MCNYFY2025 · Dec 31, 2025Shares Outstanding
996.52MSharesUpdated Sep 20, 2026Float Shares
661.54MSharesUpdated Sep 20, 2026% Held by Insiders
13.25%vs all stocks
% Held by Institutions
22.65%vs all stocks
Total Cash (MRQ)
1.26BHKD160.16M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.07HKDUpdated Sep 20, 2026Total Debt (MRQ)
414.85MHKD52.88M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3569xCurrent Ratio (MRQ)
3.34xBook Value per Share (MRQ)
1.16HKDUpdated Sep 20, 2026Total Assets
1.47BCNY219.31M · vs all stocks (USD)
Total Current Assets
1.30BCNYFY2025 · Dec 31, 2025Total Liabilities
463.28MCNYFY2025 · Dec 31, 2025Total Non-current Assets
173.31MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
253.01MCNYFY2025 · Dec 31, 2025Total Current Liabilities
210.27MCNYFY2025 · Dec 31, 2025Cash
1.09BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.09BCNYFY2025 · Dec 31, 2025Accounts Receivable
74.83MCNYFY2025 · Dec 31, 2025Inventory
121.67MCNYFY2025 · Dec 31, 2025Accounts Payable
81.65MCNYFY2025 · Dec 31, 2025Short-term Debt
48.66MCNYFY2025 · Dec 31, 2025Long-term Debt
253.01MCNYFY2025 · Dec 31, 2025Common Stock (Book)
7.22MCNYFY2025 · Dec 31, 2025Retained Earnings
-5.25BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.01BCNY150.18M · vs all stocks (USD)
Treasury Stock
411.00KCNYFY2025 · Dec 31, 202552-Week Low
1.97HKDUpdated Sep 20, 202652-Week High
4.95HKDUpdated Sep 20, 202652-Week Change
-45.76%vs all stocks
Beta
0.8010xvs all stocks
50-Day MA
2.49HKDUpdated Sep 20, 2026200-Day MA
2.93HKDUpdated Sep 20, 2026Avg 10-Day Volume
1.20MSharesUpdated Sep 20, 2026Avg 30-Day Volume
1.70MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
-0.1400HKDUpdated Sep 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.41: grey zoneSignificant
Altman Z-Score: 2.41
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Prothena Corporation plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Honz Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang East-Asia Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tuoxin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
DiaMedica Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Eikon Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Kyverna Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangxi Synergy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Kehua Bio-Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shaanxi Panlong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedMinimal Tax and Interest Drag
CSG Smart Science & Technology Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedMinimal Tax and Interest Drag
Changshu Tianyin Electromechanical Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedMinimal Tax and Interest Drag